The purpose of the Psychiatric Genomics Consortium (PGC) is to conduct meta-analyses of genome-wide genetic data for psychiatric disease. This website provides information about the organization, implementation, and results of the PGC.
The basic idea is that individual studies are generally too small to identify robust and replicable associations. Meta-analysis is a widely-used technique that can combine information across studies.
The PGC began in early 2007, and quickly became a confederation of most investigators in the field. PGC papers typically have over 200 authors. PGC scientists are from over 60 institutions in 19 countries. This is the largest consortium in the history of psychiatry, and the largest biological experiment in the field.
From 2007-11, the PGC has focused on five critically-important disorders: autism, attention-deficit hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia. In 2013, we added anorexia nervosa, OCD/Tourette's, and PTSD.
The initial intent of the PGC was to investigate the common single nucleotide polymorphisms (SNPs) genotyped on commercial arrays. The focus has expanded to include structural variation (copy number variation) and uncommon or rare genetic variation.
The PGC has received funding from many sources. Before participation in the PGC, establishing and genotyping of the primary case-control collections were funded by a wide range of national, international, and commercial funders. Funding for the PGC was for data analytical efforts. The PGC has relied heavily on the goodwill of its members and their donated effort. We are deeply grateful to the National Institute of Mental Health (NIMH) , the Netherlands Genetic Cluster Computer, Hersenstichting Nederland, and One Mind for Research for their sponsorship of the PGC.